Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alex Shimmings

Alexandra has more than 20 years' experience covering pharmaceutical and biotech R&D. An early interest in medicine, and a dawning realization that being a doctor was not for her, led to a degree in Biochemistry and Microbiology at the University of Leeds, and a move to London to pursue a career in medical journalism. Now Scrip's Managing Editor, Alex has held a variety of roles on the publication since starting as a science reporter in 1998. She instigated some of Scrip's signature features, such as the Pipeline Watch and New Active Substance lists, and also casts an editorial eye over the annual Scrip Awards. Alex's main work interests lie in novel drugs and pharmaceutical and biotech R&D, and she also enjoys medical history and current affairs.
Advertisement
Set Alert for Articles By Alex Shimmings

Latest From Alex Shimmings

VELOCITY Failure For Versartis's Lead Drug Sends Shares Into Tailspin

Versartis's long-acting growth hormone product missed Phase III non-inferiority endpoint, wiping more than 83% of the company's value.

Clinical Trials Companies

MURANO To Drive AbbVie/Roche's Venetoclax In CLL

Top-line MURANO data support Venclexta's current conditional approvals and expand its use into a broader population that should radically boost sales.

Clinical Trials Companies

Ocrevus Delay As CHMP Continues Assessment?

The CHMP's assessment of Roche's novel multiple sclerosis therapy Ocrevus continues, making a year-end approval unlikely.

Companies Approvals

PROSPECTs Futile For Bavarian Nordic's Prostvac Cancer Vaccine

The Phase III PROSPECT study's data monitoring committee decides against continuing after interim analysis. The fall-out could hit Bavarian Nordic’s CV301 too.

Cancer Clinical Trials

AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms

More Phase III data for AbbVie's selective JAK1 inhibitor upadacitinib appear to back a potential best-in-class claim but eyes remain on safety after a death from pulmonary embolism.

Clinical Trials Companies

Sanofi and Regeneron Hit Asthma Phase III Endpoints With Dupixent

Dupixent has upped the ante on Nucala and Cinqair, showing broad activity in Phase III in asthma. But will it be bested by AstraZeneca and Amgen's tezepelumab?

Clinical Trials Research & Development
See All
Advertisement
UsernamePublicRestriction

Register